Next Article in Journal
PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?
Next Article in Special Issue
The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer
Previous Article in Journal
Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models
Previous Article in Special Issue
Alterations of 5-Hydroxymethylcytosine in Human Cancers
Open AccessReview

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies

1
Department of Experimental and Clinical Sciences, University 'G. d'Annunzio', I-66013 Chieti, Italy
2
Hospital Pharmacy, "SS. Annunziata" Hospital, I-66013 Chieti, Italy
3
Oncology Department, "SS. Annunziata" Hospital, I-66013 Chieti, Italy
*
Author to whom correspondence should be addressed.
Cancers 2013, 5(3), 919-942; https://doi.org/10.3390/cancers5030919
Received: 22 April 2013 / Revised: 3 July 2013 / Accepted: 12 July 2013 / Published: 25 July 2013
(This article belongs to the Special Issue Cancer Epigenetics)
Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a variety of cytotoxic and molecular targeted agents in many different solid tumors, including breast, prostate, pancreatic, lung and ovarian cancer. Hb-HDACIs have a quite good toxicity profile and are now being tested in phase I and II clinical trials in solid tumors with promising results in selected neoplasms, such as hepatocarcinoma. This review will focus on their clinical activity and safety in patients with advanced solid neoplasms. View Full-Text
Keywords: hydroxamate-based histone deacetylase inhibitors; histone deacetylase inhibitors; vorinostat; belinostat; panobinostat; pracinostat; abexinostat; resminostat hydroxamate-based histone deacetylase inhibitors; histone deacetylase inhibitors; vorinostat; belinostat; panobinostat; pracinostat; abexinostat; resminostat
Show Figures

Figure 1

MDPI and ACS Style

Grassadonia, A.; Cioffi, P.; Simiele, F.; Iezzi, L.; Zilli, M.; Natoli, C. Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers 2013, 5, 919-942.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop